This month, we are focusing on Oncology and have reflected on the notable advancements to oncology medications in recent years.
Immunotherapy: Immunotherapy has been a significant focus in oncology. Checkpoint inhibitors, such as pembrolizumab and nivolumab have shown success in treating various cancers by targeting specific proteins that inhibit the immune system's response to cancer cells. CSI has longstanding experience sourcing these immunotherapy drugs for over 100 studies.
Targeted Therapies: Advances in understanding cancer genetics have led to the development of targeted therapies that aim to disrupt specific pathways involved in cancer growth. Drugs like imatinib and bevacizumab, which CSI have sourced for more that 35 studies, have been successful in treating cancers with specific genetic mutations. CSI has procured a wide range of these targeted therapy drugs for clinical studies worldwide.
PARP Inhibitors: Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib and rucaparib have shown efficacy in treating certain types of cancers, particularly breast cancer with BRCA mutations. Their mode of action is interfering with DNA repair mechanisms in cancer cells. CSI possesses a strong track-record sourcing this medication.
ADCs (Antibody-Drug Conjugates): ADCs are a type of targeted therapy that combines monoclonal antibodies with chemotherapy drugs. Trastuzumab emtansine (T-DM1) is an example used in breast cancer treatment and CSI has good access, finding sourcing solutions for over 50 studies.
CAR-T Cell Therapy: Chimeric Antigen Receptor T-cell (CAR-T) therapy has shown promise, particularly in haematological malignancies. This personalized treatment involves modifying a patient's T cells to express a receptor that targets cancer cells.
Adjuvant Therapies: Advances in adjuvant therapies, including post-surgical or post-chemotherapy treatments, have improved the outcomes for some cancer patients, reducing the risk of recurrence.
Precision Medicine: The concept of tailoring cancer treatment based on individual patient characteristics, including gene sequencing and other biomarkers has gained prominence, leading to more personalized and effective treatment strategies. This personalised approach is the future of cancer diagnosis and treatment.
CSI has comprehensive expertise in oncology, biologics and biosimilar products and has provided solutions to more than 1000 clinical trials all over the world, in studies developing the many types of oncology drugs explored in this article.
To find out more about how CSI can support your clinical trial, go to our Case Study and Our Services page.
.png){kind=logo}